Bispecific antibodies (bsAbs) can simultaneously bind to two separate and unique epitopes on the same or different antigens, sparking intense interest among the scientific community in recent years. Their dual [….]
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’ seasonal influenza and COVID-19 vaccines. The clinical trial combines Novavax’ recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine). Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials.
Johnson & Johnson’s pharmaceutical arm, Janssen, embarked on a global effort to combat the COVID-19 pandemic. To support their goal of supplying one billion doses of vaccine, an agreement with a contract manufacturer was reached. Large-scale manufacturing of Janssen’s vaccine would take place at the contract manufacturing site, which is designed for rapid manufacturing of vaccines and other treatments in large quantities during public health emergencies.
Baltimore Sun – Maryland-based Novavax’s effort to vaccinate the world, from zero to not quite warp speed: ‘This takes time and expertise’
On a sweltering June morning, Novavax CEO and COVID vaccine maker Stanley Erck stood on a stage unmasked and did something that would have been unthinkable six months ago: He shook hands with Maryland’s governor.
TEDCO recently launched ‘TEDCO Talks’, a series featuring thought leaders in economic development across the State of Maryland. On May 28th, TEDCO CEO & Executive Director, Troy LeMaile-Stovall interviewed Sally Allain, Head of JLABS @ Washington DC, about the future of the innovation ecosystem and the crucial role that JLABS will play in advancing the BioHealth Capital Region.
With a visit from Maryland Governor Larry Hogan at the location of their future Vaccines Innovation Campus and Global Headquarters In Gaithersburg, positive data on their COVID-19 Variant Strain Vaccine, and a Phase 3 Trial showing 90% Overall Efficacy/100% Protection Against Moderate and Severe Disease in PREVENT-19. Novavax had one of the most newsworthy weeks to kick off the Summer of 2021.
Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious
diseases. As COVID-19 spread, dozens of Maryland companies joined the global response.
Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]